[2-(4-Methyl-piperazin-1-yl)-3-phenyl-3,4-dihydro-quinazolin-4-yl]-acetic acid | 741720-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: [2-(4-Methyl-piperazin-1-yl)-3-phenyl-3,4-dihydro-quinazolin-4-yl]-acetic acid
• 英文别名: 2-[2-(4-methylpiperazin-1-yl)-3-phenyl-4H-quinazolin-4-yl]acetic acid
• CAS: 741720-06-9
• 化学式: C₂₁H₂₄N₄O₂
• 分子量: 364.447
• InChiKey: FZTNNQMGBAILQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苯甲醇 、 [2-(4-Methyl-piperazin-1-yl)-3-phenyl-3,4-dihydro-quinazolin-4-yl]-acetic acid 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 反应 5.0h， 以70%的产率得到[2-(4-Methyl-piperazin-1-yl)-3-phenyl-3,4-dihydro-quinazolin-4-yl]-acetic acid benzyl ester
  参考文献：
  名称：

  3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers

  摘要：

  For LVA T-type Ca2+ channel blockers, 3,4-dihydroquinazoline derivatives as new scaffolds were prepared and evaluated for the inhibitory activity against two members of the recombinant T-type Ca2+ channel family. Among them, 8a (KYS05001, IC50 = 0-9 muM) was nearly equipotent with mibefradil (IC50 = 0.84 muM) and inhibited LVA T-type Ca2+ channel with greater efficacy than HVA Ca2+ channel. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.090
• 作为产物：
  描述：

  methyl 2-[2-(4-methylpiperazin-1-yl)-3-phenyl-4H-quinazolin-4-yl]acetate 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以99%的产率得到[2-(4-Methyl-piperazin-1-yl)-3-phenyl-3,4-dihydro-quinazolin-4-yl]-acetic acid
  参考文献：
  名称：

  3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers

  摘要：

  For LVA T-type Ca2+ channel blockers, 3,4-dihydroquinazoline derivatives as new scaffolds were prepared and evaluated for the inhibitory activity against two members of the recombinant T-type Ca2+ channel family. Among them, 8a (KYS05001, IC50 = 0-9 muM) was nearly equipotent with mibefradil (IC50 = 0.84 muM) and inhibited LVA T-type Ca2+ channel with greater efficacy than HVA Ca2+ channel. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.090

文献信息

• METHOD OF TREATING VIRAL INFECTIONS
  申请人：EPIPHANY BIOSCIENCES

  公开号：US20150050241A1

  公开（公告）日：2015-02-19

  The present invention is directed to methods and compositions employing 9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine (“H2G”) or derivatives or analogs thereof for the treatment of viral diseases, as well as for the treatment of other conditions, including, but not limited to, cancer, chronic fatigue syndrome, Alzheimer's disease, multiple sclerosis and Graves' disease. The H2G or derivative or analog thereof can be administered in a pharmaceutical composition and can be administered with an additional antiviral therapeutic agent or another agent for the treatment of other conditions.

  本发明涉及使用9-（4-羟基-2-（羟甲基）丁基）鸟嘌呤（“H2G”）或其衍生物或类似物的方法和组合物，用于治疗病毒性疾病，以及用于治疗其他疾病，包括但不限于癌症、慢性疲劳综合征、阿尔茨海默病、多发性硬化症和格雷夫斯病。 H2G或其衍生物或类似物可以在药物组合物中给予，并且可以与其他抗病毒治疗药物或其他治疗其他疾病的药物一起给予。
• PROCESS FOR THE PREPARATION OF DIHYDROQUINAZOLINES
  申请人：Gooßen Kãthe

  公开号：US20120130072A1

  公开（公告）日：2012-05-24

  The present invention relates to a process for the preparation of dihydroquinazolines, which are used for the production of medicaments.

  本发明涉及一种制备二氢喹唑啉的方法，其用于制药。
• IDENTIFICATION OF AN ALTERED THERAPEUTIC SUSCEPTIBILITY TO ANTI-HCMV COMPOUNDS AND OF A RESISTANCE AGAINST ANTI-HCMV COMPOUNDS
  申请人：AiCuris GmbH & Co. KG

  公开号：US20140193802A1

  公开（公告）日：2014-07-10

  The present invention relates to a method for the detection of an altered therapeutic response of a subject infected by HCMV to a treatment with a 3,4 dihydroquinazoline or N-3-[(4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide, a method for the detection of a drug resistance of a HCMV to a 3,4-dihydroquinazoline or N-3-[(4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide, and to a method for the detection of a mutation of a HCMV resulting in a drug resistance to a 3,4-dihydroquinazoline or N-3-[(4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide.
• US7271260B2
  申请人：——

  公开号：US7271260B2

  公开（公告）日：2007-09-18
• US8084604B2
  申请人：——

  公开号：US8084604B2

  公开（公告）日：2011-12-27